The addiction of cancer cells to causal gene fusions often results in amplification, in vivo, which can be exploited to reveal unidentified recurrent gene rearrangements. Based on this observation, we ...

Singular Genomics Systems (NASDAQ:OMIC – Get Free Report) will likely be issuing its quarterly earnings data after the market ...

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Interestingly, it has been observed that chimeric fusion genes sometimes involve two copies of the same gene (e.g., the alcohol dehydrogenase gene in Drosophila), and when that happens ...

We have investigated the prediction of protein interactions through the analysis of domain fusion to assess whether metabolic enzymes have a higher participation in gene-fusion events compared ...

This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.